CAS 1206161-97-8
:Filgotinib
Description:
Filgotinib is a small molecule drug primarily classified as a Janus kinase (JAK) inhibitor, specifically targeting JAK1. It is designed for the treatment of autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease. The compound exhibits a selective mechanism of action, which helps to minimize off-target effects commonly associated with broader JAK inhibitors. Filgotinib is characterized by its oral bioavailability and a favorable pharmacokinetic profile, allowing for once-daily dosing. Its chemical structure includes a pyrimidine core, contributing to its potency and selectivity. The drug has undergone extensive clinical trials to evaluate its efficacy and safety, demonstrating significant improvements in disease activity among patients. As with many JAK inhibitors, potential side effects may include increased risk of infections and changes in blood parameters, necessitating careful monitoring during treatment. Overall, Filgotinib represents a targeted therapeutic option in the management of chronic inflammatory conditions.
Formula:C21H23N5O3S
InChI:InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
InChI key:InChIKey=RIJLVEAXPNLDTC-UHFFFAOYSA-N
SMILES:N(C(=O)C1CC1)C2=NN3C(=CC=CC3=N2)C4=CC=C(CN5CCS(=O)(=O)CC5)C=C4
Synonyms:- N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
- N-(5-(4-((1,1-Dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
- filgotinib (GLPG0634)
- G 146034
- GLPG 0634
- Cyclopropanecarboxamide, N-[5-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-
- CyclopropanecarboxaMide, N-[5-[4-[(1,1-dioxido-4-thioMorpholinyl)Methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-
- Filgotinib
- N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
- SYN1158
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
CAS:Formula:C21H23N5O3SPurity:98%Color and Shape:SolidMolecular weight:425.5040Ref: 54-BISN0129
1gTo inquire10mgTo inquire25mgTo inquire50mgTo inquire100mgTo inquire250mgTo inquireFilgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Formula:C21H23N5O3SPurity:98.03% - ≥95%Color and Shape:SolidMolecular weight:425.5GLPG-0634 (Filgotinib)
CAS:Controlled Product<p>Applications GLPG-0634 (Filgotinib) is a potent, selective JAK1 inhibitor. Used as an anti-inflammatory agent, it reduces levels of inflammatory cytokines in the bones and tissue of mammals.<br>References Moran, N. et al.: BioWorld Int., 16, 1 (2011);<br></p>Formula:C21H23N5O3SColor and Shape:NeatMolecular weight:425.5Filgotinib
CAS:<p>Filgotinib is an investigational drug that blocks the activity of the Janus kinase (JAK) family of enzymes. Filgotinib has been shown to have anti-inflammatory activity in vitro and in vivo, as well as to affect iron homeostasis and cytokine levels. The mechanism of action is not well understood, but it has been hypothesized that filgotinib may inhibit the production or function of cytokines such as IL-6, TNF-α, and IFN-γ. Filgotinib has also been shown to bind dextran sulfate in chromatographic analysis. It is currently being studied for its potential use in inflammatory bowel disease.</p>Formula:C21H23N5O3SPurity:Min. 95%Molecular weight:425.51 g/mol
![N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cycloprop…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039FK.jpg&w=3840&q=75)
